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The 7th edition of the ‘ESMO Sarcoma and GIST Symposium’ 
was held in Milan in February 2018. For the first time, the 
Symposium brought together representatives from the 
European Reference Network on rare adult solid cancer 
(EURACAN) joined by sarcoma experts from the USA, Japan 
and patient advocacy groups, to share insights and discuss 
future directions in this rare condition. This commentary will 
summarise the highlights in soft tissue sarcomas.
IntroduCtIon
The 7th edition of the currently named ‘ESMO 
Sarcoma and GIST Symposium’ was held in 
Milan in February 2018. So far, the sympo-
sium has taken place every 2 years and focuses 
on soft tissue sarcomas (STSs) and gastroin-
testinal stromal tumours (GIST), a group of 
rare cancers accounting for less than 1% of 
all adult solid neoplasms. For the first time, 
the 2018 event was held when EURACAN, the 
European Reference Network (ERN) on rare 
adult solid cancers (http:// euracan. ern- net. 
eu) was in place. EURACAN is a network of 
66 reference centres in rare cancers selected 
by national governments within the EU. By 
bringing together the main stakeholders in 
rare cancers, EURACAN aims to improve the 
quality of care, first of all through consen-
sus-based clinical practice guidelines, share 
best practice, disseminate patient information 
and medical education and foster research. In 
the context of this new European scenario, the 
‘2018 ESMO Sarcoma and GIST symposium’ 
brought together nearly 500 participants from 
Europe, USA and Asia, including EURACAN 
representatives, sarcoma experts, researchers 
and patients, providing a forum for the 
sarcoma community to discuss state-of-the-art 
treatments and how to move forward in this 
rare condition. This commentary will summa-
rise the highlights in STSs.
ManageMent of loCalIsed dIsease
extremity soft tissue sarcoma
Surgery is the standard treatment for extremity 
soft tissue sarcoma (ESTS). Adequate 
resection entails negative margins, the defini-
tion of which is not trivial. Sarcomas occur in 
the connective tissues and the tumour capsule 
may be part of the tumour. Hence the defini-
tion of negative margins depends on healthy 
tissue surrounding tumour surface. A soft 
tissue tumour should be excised completely 
encircled with its surrounding tissues. In this 
regard, there are natural barriers that often 
resist to sarcoma infiltration, such as muscle 
fascia, the joint capsules, the adventitia, the 
epineurium and the periosteum. If intact, 
they protect against tumour spreading. Once 
these barriers are invaded by tumour, the 
management of major vessels and nerves, 
as well as bone and joints is weighted in the 
context of disease biology and function pres-
ervation. There is evidence suggesting that 
preplanned positive margins are associated 
with a better outcome in terms of local relapse 
(LR) free-survival and cause specific survival 
compared with unexpected positive margins. 
This is particularly true if planned close dissec-
tion was performed to preserve critical struc-
tures (outcome is similar to resection with 
negative margins).1 These results point to the 
importance of considering disease biology 
when planning surgery. Along the same lines, 
the consequence of positive margins differs 
by histology. In low-grade well-differentiated 
liposarcoma, positive margins do not increase 
LR rates whereas in myxofibrosarcoma, which 
has a high risk of LR, inadvertent positive 
margins significantly increase it.2–4
Radiotherapy and chemotherapy may 
offset the negative prognostic impact of posi-
tive surgical margins, but their impact varies 
widely among histological subtypes. In two 
randomised controlled trials, radiotherapy 
decreased LR rates with no effect on overall 
survival (OS).5 Radiotherapy is a standard 
treatment for high-risk deep lesions. During 
the meeting, R. Haas presented several large 
retrospective series, which raised the possi-
bility that radiotherapy may also improve 
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OS, but concluded that high-level evidence is lacking. 
B. Catton described the caveats regarding the timing of 
radiotherapy. While neoadjuvant radiotherapy resulted 
in higher wound complications, it had better long-term 
functional outcomes. In addition, a postoperative boost of 
radiotherapy can be omitted in the neoadjuvant setting. 
Due to the complexity of decision-making in the manage-
ment of ESTS, patients should be referred to specialised 
centres.
retroperitoneal sarcoma
Surgery is the cornerstone of treatment for retroperito-
neal sarcoma (RPS). Primary surgery with clear margins 
improves outcomes and should be performed in a special-
ised sarcoma centre.6 However, tumour location and size 
limit the application of commonly used definitions of 
clear margins. During the symposium, C. Swallow showed 
that R1 rates differ between institutions and rely on 
subjective pathological evaluation. Moreover, the clinical 
significance of R1 has not been substantiated by research. 
Hence R0 and R1 should be grouped together prognosti-
cally. The value of R2 resection is questionable apart from 
palliative indications.6 Adequate surgery for RPS should 
be defined as macroscopically negative. Similar to ESTS, 
histology is important in RPS. A. Gronchi proposed a 
histology-driven choice of surgical margins, aggressively 
seeking R0 resections in diseases with a high risk of LR 
(such as liposarcoma), and a more conservative approach 
in diseases with a high risk of systemic recurrence (such as 
leiomyosarcoma). Of note, in solitary fibrous tissue (SFT), 
resection of the tumour mass with minimal margins is 
sufficient. These differences in the surgical management 
of RPS imply the need for a preoperative biopsy to plan 
the procedure.7
The difficulty of achieving a margin-free resection and the 
desire to improve long-term outcomes make multimodal 
neoadjuvant treatment an attractive option.8 The effective-
ness of radiotherapy has been reported in retrospective 
and non-controlled studies, which also found an increase 
in toxicity.9 E. Baldini argued that until the STRASS study 
(NCT01344018) is published, evidence for the use of radio-
therapy to decrease LR in RPS remains extrapolated from 
extremity STS. A preliminary report from the STRASS study 
showed that radiotherapy is safe, even when combined with 
extended surgery.9 The use of chemotherapy in the neoad-
juvant setting may downsize the tumour, improve local 
control rates and treat systemic micrometastatic disease. 
In addition, CT may also act as radiosensitiser if combined 
with RT. A phase I trial has shown that preoperative radio-
chemotherapy is feasible.10 However, there is no evidence 
that it is more effective than surgery alone. Histology may 
help exclude chemoresistant patients. Further research on 
the neoadjuvant approach should focus on the relatively 
chemosensitive histological subtypes, such as leiomyosar-
comas, undifferentiated pleomorphic sarcomas and high-
grade dedifferentiated liposarcomas. The preoperative use 
of drugs recently approved in the metastatic setting might 
widen therapeutic armamentarium.
ManageMent of advanCed dIsease
Metastatic disease develops in approximately 50% of 
patients with STS and is associated with poor prog-
nosis. Across and within STS subtypes, metastatic disease 
exhibits a wide diversity of natural history and treatment 
sensitivity, reflecting a biological heterogeneity that is 
incompletely understood.
The lungs are the main site of metastatic spread, 
although the pattern of recurrence varies according to 
the histological subtype and may include the soft tissue, 
bone, liver and even brain. P. Hohenberger provided 
the audience with an update on current practice and 
evidence relating to the resection of metachronous lung 
metastasis in patients without extrapulmonary disease. 
While evidence of the survival benefit of metastasectomy 
remains hard to formally prove, careful consideration 
of patient and disease-specific factors should inform the 
selection of patients for surgery. Factors such as a disease-
free interval of more than 1–2 years and no lesion diam-
eter exceeding 2–3 cm were associated with improved OS 
in a large retrospective review.11
Patients with synchronous and/or extrapulmonary 
metastases should be considered for systemic therapy. 
S. Patel reviewed the current standards of care, noting 
the importance of considering patient-specific goals 
of therapy and potential predictors of effect when 
sequencing and selecting therapies from the broad range 
of available agents. For example, the increased rate of 
objective response and improved progression-free survival 
(PFS), but not OS, seen with combination doxorubicin-if-
osfamide compared with doxorubicin single agent seen 
in a phase III trial suggests that the combination regime 
may be optimally employed in more chemosensitive histo-
types or when tumour shrinkage is a specific goal.12 Mean-
while, the recent provisional approval of the anti-PDGFRα 
monoclonal antibody olaratumab in combination with 
doxorubicin, based on randomised, open-label phase II 
evidence of a dramatic improvement in OS compared 
with doxorubicin single agent, indicates a potential first-
line option that may confer a survival advantage, but the 
absence of incremental gain in response rate (RR) or PFS 
needs to be considered.13
P.G. Casali outlined the evidence for histology-driven 
chemotherapy in advanced STS. The challenges of hetero-
geneity, clinical trial methodology and utility of surrogate 
efficacy endpoints were discussed as well as the potential 
applicability and integration of both prospective clinical trial 
data and retrospective case series and reports. The approval 
of the multitarget tyrosine kinase inhibitor pazopanib in 
non-adipocytic STS, and the cytotoxic agents eribulin in 
liposarcoma and trabectedin in L-sarcomas, respectively, 
reflect the improved potential of phase III studies that prese-
lect potentially sensitive trial populations based on preclin-
ical and early phase trial data.14–17 Additionally, P.G. Casali 
highlighted the valuable information that non-comparative 
phase II studies have provided for identifying STS subtypes 
with apparent drug-specific sensitivities, such as high-dose 
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continuous ifosfamide in dedifferentiated liposarcoma and 
synovial sarcoma. This approach reflects an ongoing move-
ment towards histology-driven selection of treatment while 
correlations with molecular biology across histologies are 
weak.
special entities and rare sarcomas
There is consensus in the sarcoma community that a 
histology-tailored approach should be used in several 
rare STS subtypes and this has also been incorporated 
in the recently updated joint ESMO/EURACAN Clinical 
Practice Guidelines.18 Multiple examples in the choice 
of systemic treatments were highlighted at the meeting, 
such as the peculiar activity of taxanes and gemcitabine 
in angiosarcoma and m-TOR inhibitors in malignant 
perivascular epithelioid cell tumours (PEComas), which 
are often associated with a disruption in the m-TOR 
pathway.19–21 Given the low incidence of these entities, the 
evidence for treatment is rarely from controlled studies 
and thus there is a greater degree of formal uncertainty. 
As outlined in the talk by S. Stacchiotti, solid preclinical 
data could be viewed as reducing uncertainty though in 
the face of limited direct evidence, and the example of 
imatinib in dermatofibrosarcoma protuberans (DFSP) 
was discussed. DFSP is an STS subtype in the skin with a 
translocation, t(17;22)(q22;q13), that leads to the fusion 
of collagen type 1α1 (COL1A1) and platelet-derived 
growth factor B (PDGFB). The strong preclinical rationale 
together with prospective uncontrolled data on imatinib 
activity in this subtype supported the activity and efficacy 
of imatinib in this disease from the beginning and had 
regulatory implications.22 A similar scenario exists for 
crizotinib, an anaplastic lymphoma kinase (ALK) and 
MET inhibitor, in inﬂammatory myofibroblastic tumours 
(IMT) with ALK translocations. While at the time of the 
meeting there were only retrospective clinical studies to 
support the activity of the drug in this condition,23 the 
results of the completed EORTC phase II study with 
crizotinib in IMT are now available (NCT01524926).24 
Unfortunately, only general preclinical data are avail-
able to support the activity reported in retrospective (ie, 
sunitinib25) and prospective controlled (ie, cediranib26) 
studies on antiangiogenics in alveolar soft part sarcoma, 
a disease marked by high vascularity and resistance to 
conventional chemotherapy. Similarly, there are no 
preclinical data to support the retrospective evidence 
on the efficacy of sirolimus in epithelioid haemangioen-
dothelioma,27 or the retrospective (ie, sunitinib28) and 
also uncontrolled prospective (ie, pazopanib29–31) data 
on antiangiogenics in SFT. Robust preclinical data are 
essential for accumulating evidence in rare histologies 
and potentially supporting drug approval. There was an 
agreement at the meeting on the need to work collec-
tively to foster research and improve understanding of 
the biology underlying drug activity. There was also an 
agreement to work on consensus-development initiatives 
to help shape recommendations where direct evidence is 
formally weak.
The case of histiocytic and dendritic cell neoplasms was 
also discussed during the symposium. These are a very rare 
and heterogeneous group of diseases with haematolog-
ical or mesenchymal derivation, which differ in histology, 
clinical presentation and biology. Pathologists and clini-
cians agree that histiocytic sarcoma, the most common 
subtype, and Langerhans cell sarcoma are high-grade 
aggressive diseases, but the behaviour of the remaining 
subtypes remains uncertain. Treatment of localised 
disease is based on surgery, with little data available on 
the value of radiation therapy and medical therapy. Sarco-
ma-like and lymphoma-like regimes are effective in some 
patients with advanced disease and hints of activity have 
been reported with MEK and BRAF inhibitors.32 33 In 
order to better understand biology, natural history and 
define the optimal treatment strategy, an effort within the 
sarcoma domain of EURACAN has been deployed.
Among special entities, attention was dedicated to 
desmoid-type fibromatosis during the symposium. This is a 
rare fibroblastic, proliferative, locally aggressive disease with 
no metastatic potential. Surgical resection was historically 
the mainstay of treatment, but in the last 10 years its use 
has substantially declined, as studies have documented high 
chances of stable disease with no treatment, spontaneous 
regressions and a tendency towards LR after apparently 
adequate resections.34 The value of systemic treatments for 
progressive or symptomatic patients was emphasised at the 
meeting. Significant responses have been reported with 
vinorelbine or vinblastine (with or without methotrexate), 
anthracyclines and sorafenib.35–37 The best upfront treat-
ment and the ideal sequence of compounds are uncertain. 
S. Bonvalot said there is still a role for surgery, particularly 
for the management of complications or unacceptable 
cosmetic issues. Surgery may also be considered when 
the diagnosis is unclear and disease progression could be 
life-threatening. Conversely, surgery should not be used 
in general to manage mild pain, recurrent disease, disease 
during pregnancy or postpartum or disease occurring with 
familial adenomatous polyposis.
new avenues in sts: epigenetics and immunotherapy
M. Gounder described how gene silencing through DNA 
hypermethylation at promoter and/or enhancer regions, 
mutation or post-translational modification of histones 
and deregulation of chromatin remodelling complexes 
are epigenetic mechanisms of oncogenicity across many 
different sarcoma types. Such epigenetic deregulation can 
result in the upregulation of oncogenes or the silencing of 
genes with tumour suppressor or cellular differentiation 
programming functions. Recurrent mutational deregu-
lation of the SWI-SNF chromatin-remodelling complex is 
crucial to the development of certain STS subtypes such as 
epithelioid sarcoma, malignant rhabdoid tumour, synovial 
sarcoma and a subset of chordomas. The oncogenic role 
of epigenetic deregulation is recognised in an increasing 
proportion of other STS. For example, a Cancer Genome 
Atlas study identified a subset of dedifferentiated liposar-
coma with a hypermethylated genome that is associated with 
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worse survival compared with hypomethylated tumours of 
the same subtype.38 Dr Gounder summarised the growing 
number of drugs that target epigenetic abnormalities either 
directly or through synthetic lethality and highlighted the 
use of such agents in clinical studies of STS. The combi-
nation of histone deacetylase inhibitors with other treat-
ment modalities is being investigated as a way to reverse 
chemoresistance or radioresistance in STS. EZH2 inhib-
itors have been associated with dramatic responses in 
tumours with deficient expression of the SWI-SNF member 
protein INI1.39 40 The successful development of such drugs 
will likely depend on an improved understanding of the 
dynamic biology of epigenetic deregulation and the untan-
gling of complex biomarker signatures.
The potential role of immuno-oncology in the manage-
ment of STS is under investigation. R. Maki provided the 
meeting with an update on the underlying biology of anti-
tumour immunity and the mechanisms by which cancers 
might escape this effect. S. D’Angelo summarised clin-
ical trial data on immune checkpoint inhibitors in STS. 
While use of anti-PD-1/PD-L1 in STS has produced disap-
pointing efficacy overall, there appears to be heightened 
sensitivity in certain subtypes including undifferentiated 
pleomorphic sarcoma and dedifferentiated liposarcoma.41 
Combining anti-PD-1/PD-L1 agents with anti-CTLA-4 
drugs or tyrosine kinase inhibitors may broaden and 
enhance the effect of immune checkpoint inhibitors. J.Y. 
Blay discussed translational studies that have identified 
genomic and microenvironment factors within sarcomas 
that correlate with sensitivity to immunotherapy and may 
form the basis for clinically useful biomarkers. Meanwhile, 
L. Helman summarised ongoing efforts to exploit the pres-
ence of cancer-related antigens in certain STS subtypes with 
autologous T cell therapies engineered to specifically and 
avidly target tumour cells. W. Tap suggested which drugs 
and targets should feature in the next generation of STS 
immuno-oncology trials.
Massive parallel sequencing and pathological diagnosis
Sarcomas are rare tumours featuring a relatively simple 
karyotype in a distinct proportion of cases. This should 
make it possible to identify molecular alterations that 
improve diagnostic accuracy and can be translated into 
clinically useful predictive biomarkers.
In this scenario, massive parallel sequencing (MPS) is a 
new tool with the potential to refine the pathological diag-
nosis of STS and identify novel therapeutic targets. The 
implications of recently published studies and the value of 
MPS in sarcoma were debated during the symposium. The 
results of two large retrospective studies were reported in 
2017. A study in 5635 patients with sarcoma suggested that 
MPS significantly improves diagnosis and selection of thera-
pies. MPS changed 8% of initial pathological diagnoses and 
actionable mutations were identified in 57% of patients. It 
should be noted, however, that approximately 900 patients 
lacked a precise diagnosis.42 Similarly, an analysis of the 
mutational and copy number profiles of 587 patients with 
STS found that 93% had at least one actionable mutation, 
copy number alteration and/or fusion gene.43 The data 
appear promising, but it is unclear what ‘actionable’ means 
for clinical practice, since specific drugs may be unavail-
able or (in many European countries) off-label use may be 
prohibited and in any case their actual value remains to be 
determined.44 45
Molecular diagnostic tests are currently applied to 
contribute to the diagnosis in selected groups of sarcomas 
such as translocation-related ones. Predicted biomarkers 
are still limited, best examples being represented by 
KIT/PDRGFA in GIST and ALK in IMT. A targeted MPS 
approach (meaning a selection of a limited number of 
molecular aberrations to be screened routinely) currently 
seems to be reasonable in GIST and in undifferentiated 
round cell sarcomas. In all other situations, a combina-
tion of immune-morphology and selective molecular anal-
ysis may still represent the most effective approach, but of 
course feasibility and costs could change this state of affairs 
in the near future.
The hyperbolic promises of ‘precision medicine’ has 
been boosted to suggest a ‘disease-agnostic’ approach, 
aimed to the mere identification of actionable molec-
ular targets across histologies. There was a general agree-
ment during the meeting that while it is worth screening 
for promising new specific targets such as NTRK, there is 
insufficient evidence that systematic MPS-based analysis in 
sarcoma is clinically useful. The routine role of MPS still 
remains undetermined.
In terms of ‘discovery’, two of the main diagnostic 
contributions of MPS have been the discoveries of 
STAT6 in SFT and MUC4 in low-grade fibromyxoid 
sarcoma. These are sensitive and acceptably specific 
immunomarkers that significantly improve the quality of 
sarcoma diagnosis.
In conclusion, immunomorphology and molecular 
genetics still represent the mainstay of sarcoma diag-
nosis. A rational use of MPS molecular approaches is 
certainly contributing to elucidating sarcoma pathobi-
ology. Evidence that a disease-agnostic systematic screen 
of actionable mutations is clinically relevant is still 
lacking.
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